Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies

@inproceedings{Lesueur2017PolyADPribosepolymeraseIA,
  title={Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies},
  author={Paul Lesueur and François Chevalier and Jean-Baptiste Austry and Waisse Waissi and H{\'e}l{\`e}ne Burckel and Georges No{\"e}l and J L Habrand and Yannick Saintigny and Florence Joly},
  booktitle={Oncotarget},
  year={2017}
}
BACKGROUND Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors are becoming important actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for ovarian BRCA mutated cancers and prostatic cancer. Nevertheless, PARP inhibitors are also promising drugs for combined treatments particularly with radiotherapy. More than seven PARP inhibitors have been currently developed. Central Role of PARP in DNA repair, makes consider PARP inhibitor as potential radiosensitizers, especially… CONTINUE READING